Gold Nanoparticles as a Biosensor for Cancer Biomarker Determination

Li, Chien‐Hsiu; Chan, Ming‐Hsien; Chang, Yu‐Chan; Hsiao, Michael

doi:10.3390/molecules28010364

Cited by 17 publications

(15 citation statements)

References 127 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…AuNPs-LFA, as a paper-based biosensor, fits the requirements of POC testing owing to its good selectivity, high sensitivity, low limit of detection, quick assay performance, low cost, and low sample volume ( Henderson et al, 2018 ; Bishop et al, 2019 ; Boehringer and O’Farrell, 2021 ). More importantly, AuNPs are the most suitable nanomaterial for use as an optical label in biosensors due to their biocompatibility, ease of synthesis, size-tunability, and intense red color, which is easy to detect by the naked eye ( Quesada-González and Merkoçi, 2015 ; Li et al, 2023 ). The AuNPs-LFA can readout visually the HIV-1-RT-LAMP results for anchoring anti-FAM and BSA-biotin on the NC membrane.…”

Section: Discussionmentioning

confidence: 99%

Rapid and visual identification of HIV-1 using reverse transcription loop-mediated isothermal amplification integrated with a gold nanoparticle-based lateral flow assay platform

Chen

Zhao³

et al. 2023

Front. Microbiol.

View full text Add to dashboard Cite

Human immunodeficiency virus type one (HIV-1) infection remains a major public health problem worldwide. Early diagnosis of HIV-1 is crucial to treat and control this infection effectively. Here, for the first time, we reported a novel molecular diagnostic assay called reverse transcription loop-mediated isothermal amplification combined with a visual gold nanoparticle-based lateral flow assay (RT-LAMP-AuNPs-LFA), which we devised for rapid, specific, sensitive, and visual identification of HIV-1. The unique LAMP primers were successfully designed based on the pol gene from the major HIV-1 genotypes CRF01_AE, CRF07_BC, CRF08_BC, and subtype B, which are prevalent in China. The optimal HIV-1-RT-LAMP-AuNPs-LFA reaction conditions were determined to be 68°C for 35 min. The detection procedure, including crude genomic RNA isolation (approximately 5 min), RT-LAMP amplification (35 min), and visual result readout (<2 min), can be completed within 45 min. Our assay has a detection limit of 20 copies per test, and we did not observe any cross-reactivity with any other pathogen in our testing. Hence, our preliminary results indicated that the HIV-1-RT-LAMP-AuNPs-LFA assay can potentially serve as a useful point-of-care diagnostic tool for HIV-1 detection in a clinical setting.

show abstract

Section: Discussionmentioning

confidence: 99%

Rapid and visual identification of HIV-1 using reverse transcription loop-mediated isothermal amplification integrated with a gold nanoparticle-based lateral flow assay platform

Chen

Zhao³

et al. 2023

Front. Microbiol.

View full text Add to dashboard Cite

show abstract

“…MCDA could form the basis of POC testing because it is easy to use, rapid, and cost‐saving, and it has been used to identify several important human pathogens, such as monkeypox virus, SARS‐CoV‐2, and Mycobacterium tuberculosis 13–15 . Gold‐nanoparticles‐based lateral flow biosensor (AuNPs‐LFB) is a paper‐based platform that has potential as an advanced POC diagnostic approach owing to its ease of operation, high sensitivity, low cost, and rapid detection 16,17 . This approach has become widespread in biomedical, agricultural, food safety, and environmental fields within a short period 18,19 …”

Section: Introductionmentioning

confidence: 99%

Biosensor‐based multiple cross displacement amplification platform for visual and rapid identification of hepatitis C virus

Chen,

Dong,

Shi

et al. 2024

Journal of Medical Virology

View full text Add to dashboard Cite

Hepatitis C remains a global health problem, especially in poverty‐stricken areas. A rapid and sensitive point‐of‐care (POC) diagnostic tool is critical for the early detection and timely treatment of hepatitis C virus (HCV) infection. Here, for the first time, we reported a novel molecular diagnostic assay, termed reverse transcription multiple cross displacement amplification integrated with a gold‐nanoparticle‐based lateral flow biosensor (RT‐MCDA‐AuNPs‐LFB), which was developed for rapid, sensitive, specific, and visual identification of HCV. HCV‐RT‐MCDA induced rapid isothermal amplification through a specific primer set targeting the 5′untranslated region gene from the major HCV genotypes 1b, 2a, 3b, 6a, and 3a that are prevalent in China. The optimal reaction temperature and time for RT‐MCDA‐AuNPs‐LFB were 68°C and 25 min, respectively. The limit of detection of the assay was 10 copies per test, and the specificity was 100% for the experimental strains. The whole detection procedure, including crude nucleic acid isolation (~5 min), RT‐MCDA (68°C, 25 min), and visual AuNPs‐LFB result confirmation (less than 2 min), was performed within 35 min. The preliminary results indicated that the HCV‐RT‐MCDA‐AuNPs‐LFB assay could be a valuable tool for sensitive, specific, visual, cost‐saving, and rapid detection of HCV and has potential as a POC diagnostic platform for field screening and early clinical detection of HCV infection.

show abstract

“…The AuNPs-LFB platform is portable, easy to construct and operate, highly sensitive and specific, capable of rapid detection, and provides a naked-eye visual readout [ 14 , 15 ]. More importantly, the AuNPs-LFB platform can be applied for the identification of various biomarkers, such as antigens, antibodies, nucleic acids, and infectious pathogens [ 16 , 17 ].…”

Section: Introductionmentioning

confidence: 99%

Rapid, visual, label-based biosensor platform for identification of hepatitis C virus in clinical applications

Shi,

Zhou,

Dong

et al. 2024

BMC Microbiol

View full text Add to dashboard Cite

Objectives In the current study, for the first time, we reported a novel HCV molecular diagnostic approach termed reverse transcription loop-mediated isothermal amplification integrated with a gold nanoparticles-based lateral flow biosensor (RT-LAMP-AuNPs-LFB), which we developed for rapid, sensitive, specific, simple, and visual identification of HCV. Methods A set of LAMP primer was designed according to 5’untranslated region (5’UTR) gene from the major HCV genotypes 1b, 2a, 3b, 6a, and 3a, which are prevalent in China. The HCV-RT-LAMP-AuNPs-LFB assay conditions, including HCV-RT-LAMP reaction temperature and time were optimized. The sensitivity, specificity, and selectivity of our assay were evaluated in the current study. The feasibility of HCV-RT-LAMP-AuNPs-LFB was confirmed through clinical serum samples from patients with suspected HCV infections. Results An unique set of HCV-RT-LAMP primers were successfully designed targeting on the 5’UTR gene. The optimal detection process, including crude nucleic acid extraction (approximately 5 min), RT-LAMP reaction (67℃, 30 min), and visual interpretation of AuNPs-LFB results (~ 2 min), could be performed within 40 min without specific instruments. The limit of detection was determined to be 20 copies per test. The HCV-RT-LAMP-AuNPs-LFB assay exhibited high specificity and anti-interference. Conclusions These preliminary results confirmed that the HCV-RT-LAMP-AuNPs-LFB assay is a sensitive, specific, rapid, visual, and cost-saving assay for identification of HCV. This diagnostic approach has great potential value for point-of-care (POC) diagnostic of HCV, especially in resource-challenged regions.

show abstract

Gold Nanoparticles as a Biosensor for Cancer Biomarker Determination

Cited by 17 publications

References 127 publications

Rapid and visual identification of HIV-1 using reverse transcription loop-mediated isothermal amplification integrated with a gold nanoparticle-based lateral flow assay platform

Rapid and visual identification of HIV-1 using reverse transcription loop-mediated isothermal amplification integrated with a gold nanoparticle-based lateral flow assay platform

Biosensor‐based multiple cross displacement amplification platform for visual and rapid identification of hepatitis C virus

Rapid, visual, label-based biosensor platform for identification of hepatitis C virus in clinical applications

Contact Info

Product

Resources

About